Clinical Trials Logo

Dementia clinical trials

View clinical trials related to Dementia.

Filter by:

NCT ID: NCT04701177 Enrolling by invitation - Alzheimer Disease Clinical Trials

Digitally-enhanced, Decentralized, Multi-omics Observational Cohort

ANANEOS
Start date: March 15, 2021
Phase:
Study type: Observational [Patient Registry]

The study is carried out as part of the GR2021 Priority project "Healthy Brains for life (Age 20-99): Digitally-enhanced personalized medicine study ANANEOS" and code numbered GR-00546 and it will look at the decentralized and remote assessment of the symptoms of preclinical stages in Alzheimer's disease and movement disorders, e.g. Parkinson's. For this study we are looking for participants aged over 45 without cognitive complaints or with subjective perception of cognitive decline or with mild cognitive complaints. Specific aims for the proposed study: a) to develop novel sensitive measures that can provide an early identification of those SCD and MCI individuals harboring AD pathology that are at high risk of cognitive worsening over time; b) to track pre-motor stages in Parkinson's disease and trials that enable active digital functional biomarkers; c) to track disease progression during pre-dementia and pre-motor stages in clinical practice and trials with measures that enable to capture subtle changes.

NCT ID: NCT04680130 Enrolling by invitation - Parkinson Disease Clinical Trials

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

AND1
Start date: November 1, 2020
Phase:
Study type: Observational

The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.

NCT ID: NCT04675229 Enrolling by invitation - Dementia Clinical Trials

Extending the Validation of SCREEN to Persons Living With Dementia or in Retirement Homes

SCREEN
Start date: September 25, 2022
Phase:
Study type: Observational

Older adults (≥ 55 years) who do not eat enough nutritious food are at risk of malnutrition. Malnutrition can lead to frailty, hospitalization, poor quality of life, and death. SCREEN (Seniors in the Community Risk Evaluation for Eating and Nutrition) is the leading nutrition risk screening tool for cognitively well older adults living in the community. The purpose of this study is to determine if SCREEN can be used to find nutrition risk among older adults diagnosed with mild cognitive impairment or dementia (i.e., MCI-D) living in the community and persons living in retirement homes. SCREEN and other nutrition and health measures will be completed in 600 older adults (300 living in retirement homes with or without MCI-D, and 300 living with MCI-D in the community). SCREEN will be completed twice to determine reliability, and persons with MCI-D will have their results compared to those of a caregiver who completes it on their behalf. A dietitian's assessment and rating of nutrition risk will be used as the gold-standard to determine validity.

NCT ID: NCT04635540 Enrolling by invitation - Parkinson Disease Clinical Trials

Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease

Empathy
Start date: July 22, 2019
Phase: N/A
Study type: Interventional

This study evaluates an educational brochure tailored to caregivers of people with Alzheimer's disease, Parkinson's disease dementia, Lewy body disease, frontotemporal dementia, and vascular disease dementia. The goal of the brochure is educating caregivers about the decreased ability to detect emotion and decreased empathy that can be seen in dementia, increasing caregiver competence in providing care, and teaching caregivers ways to manage over time that lessens burden and improves quality of life.

NCT ID: NCT04510168 Enrolling by invitation - Alzheimer Disease Clinical Trials

Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease

Start date: September 18, 2020
Phase:
Study type: Observational

The aging of the United States (US) population will lead to a steep rise in Alzheimer disease (AD). There is an urgent need for novel therapies that may tackle this looming societal problem. People with Alzheimer disease have frequently evidence of vascular disease in the brain, and vascular disease can increase the risk of Alzheimer disease. Based on this finding, the investigators plan to expand the understanding of how vascular disease contributes to Alzheimer disease, hoping to identify novel target to modify the natural progression of the disease. The investigators will accomplish this goal by inviting 300 participants (with and without dementia) of the Northern Manhattan Study (NOMAS) to undergo a brain magnetic resonance imaging (MRI) and donate blood. Of the 300 participants enrolled, 60 participants will be randomly selected to undergo Aβ and tau positron emission tomography (PET) imaging. From the brain MRI, the investigators will obtain measurements of cerebrovascular disease and relate the to the risk of Alzheimer disease. With the blood, the investigators hope to identify measures of aging and inflammation that may predict changes noted in brain scan and identify people at a higher risk of dementia. The investigators will examine PET markers of inflammation and aging in the brain and how the markers relate to dementia.

NCT ID: NCT04443621 Enrolling by invitation - Dementia Clinical Trials

Changes in the Perception of Personal Dignity Over the Course of Dementia

DIDEM
Start date: July 1, 2020
Phase:
Study type: Observational

Dignity is an integral part of quality of life (QoL). Older adults often face with situations that are related with the development of dementia and that might significantly affect their feeling of personal dignity. The aim of the project is to investigate the changes in the perception of personal dignity amongst older adults with dementia (OAwD) over the course of three years and to define factors that threaten their dignity. A mixed methods design (longitudinal prospective study) will be used. In the quantitative part, a battery of Czech questionnaires will be used, and a translation and validation of a Czech version of the ACE-III will be carried out. The qualitative part will include in-depth interviews (narrative and semi-structured). The sample will comprise of OAwD living in home setting. Knowledge of the changes in the perception of personal dignity and related factors may aid the healthcare staff in choosing interventions that support and preserve dignity of OAwD as a significant part of their QoL. The project is a follow-up of a previous project No. 16-28628A.

NCT ID: NCT04250376 Enrolling by invitation - Parkinson Disease Clinical Trials

The Use of Transcranial Focused Ultrasound for the Treatment of Neurodegenerative Dementias

Start date: November 27, 2017
Phase: N/A
Study type: Interventional

The purpose of this open label study is to evaluate longer term tolerability and early efficacy of transcranial ultrasound in the treatment of patients with mild cognitive impairment or dementia.

NCT ID: NCT04146545 Enrolling by invitation - Clinical trials for Health Related Social Needs (HRSN)

CommunityRx-Dementia

CRx-D
Start date: December 16, 2019
Phase: N/A
Study type: Interventional

Caregivers of home-dwelling people with Alzheimer's Disease and related dementias (ADRD) are one of the most rapidly growing populations in the United States. Among ADRD caregivers with unmet health-related social needs, this study aims to evaluate the effects of the CRx-D intervention versus usual care on caregiver self-efficacy.

NCT ID: NCT04060082 Enrolling by invitation - Clinical trials for Frontotemporal Dementia

Voices Of Individuals: Challenges and Experiences Of bvFTD

Start date: June 26, 2019
Phase:
Study type: Observational

The VOICE Of bvFTD study is a telephone interview research study about life with or at risk for behavioral variant frontotemporal dementia (bvFTD). The study aims to understand how bvFTD impacts individuals' day to day lives, how people think about themselves, and what challenges they face.

NCT ID: NCT04054648 Enrolling by invitation - Hypertension Clinical Trials

BedMed-Frail: Does the Potential Benefit of Bedtime Antihypertensive Prescribing Extend to Frail Populations?

Start date: May 14, 2020
Phase: N/A
Study type: Interventional

High blood pressure (present in 1 of 5 Canadian adults) increases the risk of heart attack and stroke. Blood pressure lowering pills reduce this risk - but perhaps not optimally. A Spanish study suggests that using blood pressure pills at bedtime, instead of in the morning (when they are most commonly used), reduces death, heart attack, and stroke by more than 50%. If true, a switch to bedtime prescribing would have more impact on the health of those with high blood pressure than whether high blood pressure is treated at all. BedMed, a community-based Canadian primary care trial, is already running and looking both to validate the findings of this Spanish study and to determine whether there might be unrecognized harms of bedtime use (such as more falls and fractures as a result of lower overnight blood pressure). One very important population that is likely to be more sensitive to the effects of medications, and almost always excluded from randomized trials, are the frail elderly (such as those who are resident in nursing homes). In order to have the greatest information about the safety and effectiveness of bedtime blood pressure medications, the BedMed team is additionally conducting a similar trial to BedMed in nursing homes ("BedMed-Frail" - the subject of this trial registration) to determine whether the risks and benefits of bedtime prescribing differ in this highly understudied population. Basics of the trial: When patients are admitted to nursing homes, neither they nor their physicians are consulted about the timing of blood pressure medication. Unless explicitly stated to be otherwise, blood pressure pills are instead largely arbitrarily assigned for morning use by default. Given there is evidence that bedtime administration may be safer, the nursing homes participating in BedMed-Frail will have each hypertensive resident randomized to either continue with morning blood pressure medication use, as is their norm, or to have their facility's pharmacist gradually switch each residents blood pressure pills to bedtime. Over a period of roughly 3 years, health outcomes in these facilities will be tracked using routinely collected electronic health data to determine differences in things like hospitalization, death, or hip fractures - and at the end of the study the investigators hope to determine whether or not the recommendations for blood pressure medication timing in frail older adults should differ from those for the general population.